Context Therapeutics Inc. (CNTX) Form 8-K — May 18, 2026
Context Therapeutics (CNTX) has amended its license agreement with BioAtla (BCAB) to permanently buy out all future milestone and royalty obligations for its CT-202 program. The company agreed to pay a total of $6.5 million, consisting of a $4.5 million upfront payment and a $2.0 million payment due by August 1, 2026. In exchange for these payments, Context secured an irrevocable, royalty-free, fully paid-up, and non-terminable license to CT-202, a Nectin-4 x CD3 bispecific antibody. This amendment eliminates BioAtla’s rights to terminate the agreement and removes Context’s reporting and R&D obligations to BioAtla.
Key figures
- Second Payment
- 2000000
- Upfront Payment
- 4500000
- License Type
- irrevocable, royalty-free, fully paid-up, non-terminable
- Payment Due Date1
- within 5 business days of May 14, 2026
- Payment Due Date2
- August 1, 2026
Price after filing
Close on the filing date to close N calendar days later (from $2.15). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.